1. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy.
- Author
-
Lian, Caixia, Ruan, Lingling, Shang, Dongsheng, Wu, Yanfang, Lu, Yongjin, Lü, Peng, Yang, Yuhua, Wei, Yajun, Dong, Xiaojing, Ren, Dewan, Chen, Keping, Liu, Hanqing, Tu, Zhigang, and Lü, Peng
- Subjects
- *
BREAST cancer treatment , *HEPARIN , *EPIDERMAL growth factor , *AUTOCRINE mechanisms , *TARGETED drug delivery , *DRUG resistance in cancer cells , *ANTINEOPLASTIC agents , *BREAST tumors , *DRUG therapy , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *EVALUATION research - Abstract
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) belongs to the EGF family and exhibits its activity after binding to its receptors in autocrine, paracrine, and juxtacrine interactions. HB-EGF plays important roles in several biological and pathological processes, such as wound healing, blastocyst implantation, atherosclerosis, and heart development. Clinical studies have shown that HB-EGF is closely correlated with tumorigenesis, metastasis, and drug resistance in breast cancer. Specifically, targeted inhibition of HB-EGF improves the therapeutic efficacy and suppresses the tumor progression. This review discusses the importance of HB-EGF in mammary carcinoma progression and the potential value of HB-EGF as a therapeutic target for breast cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF